Market Place
Sourcing Support
CytomX Therapeutics Reports Q3 2024 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Report Q3 2024 Results on Nov 7, 2024
31 Oct 2024 //
GLOBENEWSWIRE
CytomX Announces First Patient Dosed With CX-801
09 Sep 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
CytomX To Report Q2 2024 Results On August 8
01 Aug 2024 //
GLOBENEWSWIRE
CytomX To Present At H.C. Wainwright Immune Cell Engager Virtual Conference
18 Jun 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Promotes Chris Ogden To Chief Financial Officer
17 Jun 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
22 May 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Announces New Employment Inducement Grants
16 May 2024 //
GLOBENEWSWIRE
CytomX shares plummet as Amgen-partnered cancer drug yields jumbled Phase 1 data
09 May 2024 //
ENDPTS
CytomX Q1 2024 Results, Business Update
08 May 2024 //
GLOBENEWSWIRE
CytomX Positive Phase 1a Data For CX-904 PROBODY Candidate
08 May 2024 //
GLOBENEWSWIRE
CytomX Collaboration to Evaluate CX-801 + KEYTRUDA®
07 May 2024 //
GLOBENEWSWIRE
CytomX Q1 2024 Results, CX-904 Phase 1a Data Update On May 8
01 May 2024 //
GLOBENEWSWIRE
CytomX Announces First Dosed with CX-2051 in a Ph 1 Study for Neoplasms
08 Apr 2024 //
GLOBENEWSWIRE
CytomX Announces Nomination of Candidate in PROBODY TCB Collab with Astellas
03 Apr 2024 //
GLOBENEWSWIRE
CytomX Achieves $5M Astellas Milestone
03 Apr 2024 //
CONTRACT PHARMA
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
21 Mar 2024 //
GLOBENEWSWIRE
CytomX Announces Achievement in PROBODY® TCB Collaboration with Astellas
18 Mar 2024 //
GLOBENEWSWIRE
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
13 Mar 2024 //
FIERCE BIOTECH
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
11 Mar 2024 //
GLOBENEWSWIRE
CytomX to Report Fourth Quarter and Full Year 2023 Financial Results
04 Mar 2024 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming March Investor Conferences
27 Feb 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051
24 Jan 2024 //
GLOBENEWSWIRE
CytomX to Present at the B. Riley Securities Annual Oncology Conference
12 Jan 2024 //
GLOBENEWSWIRE
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
04 Jan 2024 //
GLOBENEWSWIRE
CytomX to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
GLOBENEWSWIRE
Xencor pulls back from Genentech cancer pact to cut costs
08 Nov 2023 //
FIERCE BIOTECH
CytomX Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming November Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
CytomX to Report Third Quarter 2023 Financial Results on November 7, 2023
31 Oct 2023 //
GLOBENEWSWIRE
CytomX to Present Data for Conditionally Activated Interferon Alpha-2b
30 Oct 2023 //
GLOBENEWSWIRE
CytomX Presents Profile of EpCAM-directed Antibody Drug Conjugate CX-2051
18 Oct 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming September Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
CytomX to Present at H.C. Wainwright Immune Cell Engager Virtual Conference
10 Aug 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
CytomX to Report Second Quarter 2023 Financial Results on August 8, 2023
01 Aug 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Announces New Employment Inducement Grants
20 Jul 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
17 Jul 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Announces $30 M Private Placement from BVF Partners L.P.
30 Jun 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Reports1Q 2023 FYR and Provides Business Update
09 May 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9,2023
01 May 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect at NASDAQ
25 Apr 2023 //
GLOBENEWSWIRE
AbbVie drops CytomX partnership, leaving PhII program in the air
29 Mar 2023 //
ENDPTS
CytomX Reports Full Year 2022 Financial Results and Provides Business Update
27 Mar 2023 //
GLOBENEWSWIRE
CytomX to Report Q4 and Full Year 2022 Financial Results on March 27, 2023
22 Mar 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming March Investor Conferences
28 Feb 2023 //
GLOBENEWSWIRE
Harvard Bioscience Schedules Fourth Quarter 2022 Earnings Conference
28 Feb 2023 //
GLOBENEWSWIRE
CytomX Announces Milestone Achievement in Probody TCB Collaboration with Astellas
26 Jan 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the B. Riley Securities Investor Conference
17 Jan 2023 //
GLOBENEWSWIRE
Moderna teams up with CytomX in mRNA pact potentially worth over $1.2 billion
06 Jan 2023 //
GLOBENEWSWIRE
CytomX Therapeutics Provides Business Update and Outlines 2023 Company
05 Jan 2023 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare
20 Dec 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Present Ph2 Data for Praluzatamab Ravtansine (CX-2009)
07 Dec 2022 //
GLOBENEWSWIRE
Regeneron swoops in with $2B biobucks pact for troubled CytomX
18 Nov 2022 //
FIERCEBIOTECH
CytomX Therapeutics Reports3Q 2022 Financial Results & Provides Update
08 Nov 2022 //
GLOBENEWSWIRE
CytomX to Present Preclinical for Conditionally Activated Interferon Alpha-2b
07 Nov 2022 //
GLOBENEWSWIRE
CytomX Therapeutics to Present at Upcoming November Investor Conferences
02 Nov 2022 //
GLOBENEWSWIRE
